JP4651280B2 - 血管内人工器具用eptfe被覆材 - Google Patents
血管内人工器具用eptfe被覆材 Download PDFInfo
- Publication number
- JP4651280B2 JP4651280B2 JP2003530345A JP2003530345A JP4651280B2 JP 4651280 B2 JP4651280 B2 JP 4651280B2 JP 2003530345 A JP2003530345 A JP 2003530345A JP 2003530345 A JP2003530345 A JP 2003530345A JP 4651280 B2 JP4651280 B2 JP 4651280B2
- Authority
- JP
- Japan
- Prior art keywords
- layer
- substances
- eptfe
- composite device
- microns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000576 coating method Methods 0.000 title description 6
- 239000011248 coating agent Substances 0.000 title description 5
- 239000002131 composite material Substances 0.000 claims description 103
- 239000000126 substance Substances 0.000 claims description 84
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 claims description 83
- 230000000975 bioactive effect Effects 0.000 claims description 38
- 238000012384 transportation and delivery Methods 0.000 claims description 37
- 239000013543 active substance Substances 0.000 claims description 34
- 239000011148 porous material Substances 0.000 claims description 31
- 238000002513 implantation Methods 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 18
- 239000002861 polymer material Substances 0.000 claims description 16
- 229920001059 synthetic polymer Polymers 0.000 claims description 13
- 239000003146 anticoagulant agent Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 229920005615 natural polymer Polymers 0.000 claims description 10
- 230000035699 permeability Effects 0.000 claims description 10
- 230000033228 biological regulation Effects 0.000 claims description 9
- 210000004204 blood vessel Anatomy 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 230000002785 anti-thrombosis Effects 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 230000007246 mechanism Effects 0.000 claims description 5
- -1 polyethylene Polymers 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 102000016942 Elastin Human genes 0.000 claims description 4
- 108010014258 Elastin Proteins 0.000 claims description 4
- 102000009123 Fibrin Human genes 0.000 claims description 4
- 108010073385 Fibrin Proteins 0.000 claims description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 230000002927 anti-mitotic effect Effects 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 230000022131 cell cycle Effects 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 229920002549 elastin Polymers 0.000 claims description 4
- 229950003499 fibrin Drugs 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 102000007547 Laminin Human genes 0.000 claims description 3
- 108010085895 Laminin Proteins 0.000 claims description 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 229920002732 Polyanhydride Polymers 0.000 claims description 3
- 239000004695 Polyether sulfone Substances 0.000 claims description 3
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 3
- 229920001710 Polyorthoester Polymers 0.000 claims description 3
- 229920000388 Polyphosphate Polymers 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 108010031318 Vitronectin Proteins 0.000 claims description 3
- 102100035140 Vitronectin Human genes 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 210000002469 basement membrane Anatomy 0.000 claims description 3
- 239000012867 bioactive agent Substances 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 229960002086 dextran Drugs 0.000 claims description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000000122 growth hormone Substances 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 3
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 3
- 239000002745 poly(ortho ester) Substances 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 229920001281 polyalkylene Polymers 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229920006393 polyether sulfone Polymers 0.000 claims description 3
- 239000004633 polyglycolic acid Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 239000001205 polyphosphate Substances 0.000 claims description 3
- 235000011176 polyphosphates Nutrition 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229920001289 polyvinyl ether Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229940032147 starch Drugs 0.000 claims description 3
- 230000036262 stenosis Effects 0.000 claims description 3
- 208000037804 stenosis Diseases 0.000 claims description 3
- 229940005605 valeric acid Drugs 0.000 claims description 3
- 230000002227 vasoactive effect Effects 0.000 claims description 3
- 229940124549 vasodilator Drugs 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 239000004698 Polyethylene Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 239000010410 layer Substances 0.000 description 131
- 239000003814 drug Substances 0.000 description 43
- 229940079593 drug Drugs 0.000 description 36
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 17
- 239000004810 polytetrafluoroethylene Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 238000003475 lamination Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 10
- 230000002792 vascular Effects 0.000 description 10
- 239000011859 microparticle Substances 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000005245 sintering Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 238000005470 impregnation Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 229920001410 Microfiber Polymers 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000012438 extruded product Nutrition 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000011229 interlayer Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 239000003658 microfiber Substances 0.000 description 2
- 210000001724 microfibril Anatomy 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- VNDNKFJKUBLYQB-UHFFFAOYSA-N 2-(4-amino-6-chloro-5-oxohexyl)guanidine Chemical compound ClCC(=O)C(N)CCCN=C(N)N VNDNKFJKUBLYQB-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229940123011 Growth factor receptor antagonist Drugs 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A61F2002/072—Encapsulated stents, e.g. wire or whole stent embedded in lining
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Vascular Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Medicinal Preparation (AREA)
Description
例1においては、いくつかのePTFE被覆材を製造し、多孔度試験を行った。これらの結果が図11のグラフに示してある。図11におけるT/T、S/T及びT/S/Tは、それぞれ比較例、本発明の実施例1及び実施例2を表す。
図11において、管/管(T/T)は、下記の構造を有する脈管内グラフト(EVG)を表す。
外部層:節間距離20〜30μmのePTFEグラフト
内部層:節間距離40〜60μmのePTFEグラフト
実施例1
シート/管(S/T)は、下記の構造を有する脈管内グラフト(EVG)を表す。
外部層:節間距離5〜10μmのePTFEグラフト/シート
内部層:節間距離40〜60μmのePTFEグラフト
実施例2
管/シート/管(T/S/T)は、下記の構造を有する脈管内グラフト(EVG)を表す。
外部層:節間距離20〜30μmのePTFEグラフト
中間層:節間距離5〜10μmのePTFEグラフト/シート
内部層:節間距離40〜60μmのePTFEグラフト
実施例3
外部層:節間距離20〜30μmのePTFEグラフト
中間層:節間距離5〜10μmのePTFEグラフト
内部層:節間距離40〜60μmのePTFEグラフト
結果は不対t検定により解析し、0.05未満の確率値(P)のみを有意と考えた。
Claims (29)
- 埋込部位に関する1つ以上の生理活性物質の送達を調節するための埋込型の複合器具において、
(a)上記1つ以上の生理活性物質と、
(b)細胞内皮化を促進するのに十分な第1の多孔度を有するePTFEからなり、内腔層である第1層と、
(c)上記第1層の周囲に配置され、通り抜ける上記生理活性物質の送達の調節を可能にする第2の多孔度を有し、ポリマ材料からなる第2層であって、
上記第2層が内部にリザーバーを有し、前記リザーバーはリザーバー壁を有し、及びリザーバー中の生理活性物質がリザーバー壁を通り抜けて、第2層を形成するポリマ材料中に拡散するのに十分な透過性を有する多孔性ポリマ材料で形成されている、第2層と
(d)上記第2層の周囲に配置され、ePTFEからなり、第3の多孔度を有し、上記第1層の半径方向強度を上回る半径方向強度を示す第3層とを有し、
上記第2の多孔度は、上記第1層と上記第3層との間への細胞の侵入を調節する、複合器具。 - 上記リザーバーの内部に上記1つ以上の生理活性物質が埋め込まれていることを特徴とする請求項1記載の複合器具。
- 上記第2層の外側に上記1つ以上の生理活性物質がコーティングされていることを特徴とする請求項1記載の複合器具。
- 該複合器具が管状部材であることを特徴とする請求項1記載の複合器具。
- 上記第2層は、節間距離約5〜約10ミクロンの細孔を有するePTFEからなることを特徴とする請求項1記載の複合器具。
- 上記第2層は、結節/フィブリルの位置関係が約5〜約10ミクロンであることを特徴とする請求項5記載の複合器具。
- 上記第1層が節間距離40ミクロン以上の細孔を有し、
上記第3層が節間距離40ミクロン未満の細孔を有することを特徴とする請求項1記載の複合器具。 - 上記第2層を形成するポリマ材料は、合成ポリマ、天然ポリマ又はそれらの組合せからなるグループから選択されることを特徴とする請求項1記載の複合器具。
- 上記合成ポリマは、ePTFE、ポリウレタン、ポリアクリルアミド、ポリビニルアルコール、ポリリン酸塩エステル、ポリエーテルスルホン、ポリオルトエステル、ポリエステル、シロキサンポリマ、シリコーン、ポリビニルピロリドン、ポリビニルエーテル、ポリカーボネート、ポリアルキレン、ポリアミド、ポリ無水物、酸化ポリエチレン、芳香族ポリビニル、吉草酸ポリヒドロキシ酪酸塩、ポリヒドロキシ酪酸塩−コ−ヒドロキシ吉草酸塩、ポリアクリル酸、並びにそれらの誘導体及び混合物からなるグループから選択されることを特徴とする請求項8記載の複合器具。
- 上記天然ポリマは、フィブリン、エラスチン、セルロース、コラーゲン、ゼラチン、ビトロネクチン、フィブロネクチン、ラミニン、再構成基底膜基質、デンプン、デキストラン、アルギン酸塩、ヒアルロン酸、ポリラクト酸、ポリグリコール酸、ポリペプチド、グリコサミノグリカン、並びにそれらの誘導体及び混合物からなるグループから選択されることを特徴とする請求項8記載の複合器具。
- 上記天然ポリマ及び上記合成ポリマは、生体安定性又は生体吸収性ポリマであることを特徴とする請求項8記載の複合器具。
- 埋込部位に関する1つ以上の生理活性物質の送達を調節するための埋込型の複合器具において、
節間距離が40ミクロン以上の細孔を有するePTFEからなり、内腔層である第1層と、
上記第1層の周囲に配置され、ePTFEからなる第2層と、
上記第2層の周囲に配置され、節間距離が40ミクロン未満の細孔を有するePTFEからなる第3層とを有し、
上記第2層は、節間距離が約5〜約10ミクロンであり、且つ結節/フィブリルの位置関係が約5〜約10ミクロンである細孔を有し、該第2層を通り抜ける天然又は合成生理活性物質の送達の調節を可能にし、上記第2層が内部にリザーバーを有し、前記リザーバーはリザーバー壁を有し、及びリザーバー中の生理活性物質がリザーバー壁を通り抜けて、第2層を形成するePTFE中に拡散するのに十分な透過性を有する多孔性ポリマ材料で形成されている、
ことを特徴とする複合器具。 - 埋込部位に関する1つ以上の生理活性物質の送達を調節するための埋込型の複合器具において、
節間距離が40ミクロン未満の細孔を有するePTFEからなり、内腔層である第1層と、
上記第1層の周囲に配置され、ePTFEからなる第2層と、
上記第2層の周囲に配置され、節間距離が40ミクロン以上の細孔を有するePTFEからなる第3層とを有し、
上記第2層は、節間距離が約5〜約10ミクロンであり、且つ結節/フィブリルの位置関係が約5〜約10ミクロンである細孔を有し、該第2層を通り抜ける天然又は合成生理活性物質の送達の調節を可能にし、
上記第2層が内部にリザーバーを有し、前記リザーバーはリザーバー壁を有し、及びリザーバー中の生理活性物質がリザーバー壁を通り抜けて、第2層を形成するePTFE中に拡散するのに十分な透過性を有する多孔性ポリマ材料で形成されている、
ことを特徴とする複合器具。 - 上記第1層と上記第2層との間に埋込型補綴ステントをさらに有することを特徴とする請求項1、請求項12又は請求項13のいずれか1項に記載の複合器具。
- 上記第2層と上記第3層との間に埋込型補綴ステントをさらに有することを特徴とする請求項1、請求項12又は請求項13のいずれか1項に記載の複合器具。
- 上記1つ以上の生理活性物質は、成長因子、抗凝血物質、狭窄抑制物質、抗血栓物質、抗生物質、抗腫瘍物質、抗増殖物質、成長ホルモン、抗ウイルス物質、抗血管形成物質、血管形成物質、抗有糸分裂物質、抗炎症物質、細胞周期調節物質、遺伝物質、コレステロール降下物質、血管拡張物質、内因性血管作用機序を阻害する物質、ホルモン、それらの同族体、誘導体、断片、薬用塩、及びそれらの組合せからなるグループから選択されることを特徴とする請求項8、請求項12又は請求項13のいずれか1項に記載の複合器具。
- 埋込部位に関する1つ以上の生理活性物質の送達を調節するための埋込型の複合器具を製造する方法において、
第1の多孔度を有するePTFE材料からなり、内腔層である第1層を準備するステップと、
第2の多孔度を有し、天然又は合成ポリマ材料からなる第2層を上記第1層の周囲に配置するステップと、
第3の多孔度を有し、ePTFE材料からなる第3層を上記第2層の周囲に配置するステップとを有し、
上記第2層は、該第2層を通り抜ける上記1つ以上の生理活性物質の送達の調節を可能にし、上記第2層が内部にリザーバーを有し、前記リザーバーはリザーバー壁を有し、及びリザーバー中の生理活性物質がリザーバー壁を通り抜けて、第2層を形成するポリマ材料中に拡散するのに十分な透過性を有する多孔性ポリマ材料で形成されている、
することを特徴とする複合器具の製造方法。 - さらに埋込型補綴ステントを上記第1層と上記第2層との間に挿入することを特徴とする請求項17記載の複合器具の製造方法。
- さらに埋込型補綴ステントを上記第2層と上記第3層との間に挿入することを特徴とする請求項17記載の複合器具の製造方法。
- 上記第2層は、節間距離が約5〜約10ミクロンである細孔を有するePTFEからなることを特徴とする請求項17記載の複合器具の製造方法。
- 上記第2層は、結節/フィブリルの位置関係が約5〜約10ミクロンであることを特徴とする請求項20記載の複合器具の製造方法。
- 上記第3層は、上記第1層の半径方向強度を上回る半径方向強度を示すことを特徴とする請求項17記載の複合器具の製造方法。
- 上記ePTFEからなる第1層は、節間距離が40ミクロン以上の細孔を有し、
上記ePTFEからなる第3層は、節間距離が40ミクロン未満の細孔を有することを特徴とする請求項22記載の複合器具の製造方法。 - 上記第1層は、上記第3層の半径方向強度を上回る半径方向強度を示すことを特徴とする請求項17記載の複合器具の製造方法。
- 上記ePTFEからなる第1層は、節間距離が40ミクロン未満の細孔を有し、
上記ePTFEからなる第3層は、節間距離が40ミクロン以上の細孔を有することを特徴とする請求項24記載の複合器具の製造方法。 - 前記合成ポリマは、ePTFE、ポリウレタン、ポリアクリルアミド、ポリビニルアルコール、ポリリン酸塩エステル、ポリエーテルスルホン、ポリオルトエステル、ポリエステル、シロキサンポリマ、シリコーン、ポリビニルピロリドン、ポリビニルエーテル、ポリカーボネート、ポリアルキレン、ポリアミド、ポリ無水物、酸化ポリエチレン、芳香族ポリビニル、吉草酸ポリヒドロキシ酪酸塩、ポリヒドロキシ酪酸塩-コ-ヒドロキシ吉草酸塩、ポリアクリル酸、並びにそれらの誘導体及び混合物からなるグループから選択されることを特徴とする請求項17記載の複合器具の製造方法。
- 上記天然ポリマは、フィブリン、エラスチン、セルロース、コラーゲン、ゼラチン、ビトロネクチン、フィブロネクチン、ラミニン、再構成基底膜基質、デンプン、デキストラン、アルギン酸塩、ヒアルロン酸、ポリラクト酸、ポリグリコール酸、ポリペプチド、グリコサミノグリカン、並びにそれらの誘導体及び混合物からなるグループから選択されることを特徴とする請求項17記載の複合器具の製造方法。
- 上記天然ポリマ及び上記合成ポリマは、生体安定性ポリマ又は生体吸収性ポリマであることを特徴とする請求項17記載の複合器具の製造方法。
- 上記1つ以上の生理活性物質は、増殖因子、抗凝血物質、狭窄抑制物質、抗血栓物質、抗生物質、抗腫瘍物質、抗増殖物質、成長ホルモン、抗ウイルス物質、抗血管形成物質、血管形成物質、抗有糸分裂物質、抗炎症物質、細胞周期調節物質、遺伝物質、コレステロール降下物質、血管拡張物質、内因性血管作用機序を阻害する物質、ホルモン、それらの同族体、誘導体、断片、薬用塩、及びそれらの組合せからなるグループから選択されることを特徴とする請求項17記載の複合器具の製造方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/962,062 US6827737B2 (en) | 2001-09-25 | 2001-09-25 | EPTFE covering for endovascular prostheses and method of manufacture |
PCT/US2002/022596 WO2003026713A1 (en) | 2001-09-25 | 2002-07-16 | Eptfe covering for endovascular prostheses |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005503240A JP2005503240A (ja) | 2005-02-03 |
JP4651280B2 true JP4651280B2 (ja) | 2011-03-16 |
Family
ID=25505375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003530345A Expired - Fee Related JP4651280B2 (ja) | 2001-09-25 | 2002-07-16 | 血管内人工器具用eptfe被覆材 |
Country Status (5)
Country | Link |
---|---|
US (1) | US6827737B2 (ja) |
EP (2) | EP1429816A1 (ja) |
JP (1) | JP4651280B2 (ja) |
CA (1) | CA2465704C (ja) |
WO (1) | WO2003026713A1 (ja) |
Families Citing this family (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7351421B2 (en) * | 1996-11-05 | 2008-04-01 | Hsing-Wen Sung | Drug-eluting stent having collagen drug carrier chemically treated with genipin |
US6395019B2 (en) | 1998-02-09 | 2002-05-28 | Trivascular, Inc. | Endovascular graft |
US7713297B2 (en) | 1998-04-11 | 2010-05-11 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
US7128073B1 (en) | 1998-11-06 | 2006-10-31 | Ev3 Endovascular, Inc. | Method and device for left atrial appendage occlusion |
US7044134B2 (en) | 1999-11-08 | 2006-05-16 | Ev3 Sunnyvale, Inc | Method of implanting a device in the left atrial appendage |
US8382821B2 (en) | 1998-12-03 | 2013-02-26 | Medinol Ltd. | Helical hybrid stent |
US20040267349A1 (en) | 2003-06-27 | 2004-12-30 | Kobi Richter | Amorphous metal alloy medical devices |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US10398830B2 (en) * | 2000-11-17 | 2019-09-03 | Vactronix Scientific, Llc | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US7560006B2 (en) | 2001-06-11 | 2009-07-14 | Boston Scientific Scimed, Inc. | Pressure lamination method for forming composite ePTFE/textile and ePTFE/stent/textile prostheses |
AU2002345328A1 (en) | 2001-06-27 | 2003-03-03 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US7147661B2 (en) * | 2001-12-20 | 2006-12-12 | Boston Scientific Santa Rosa Corp. | Radially expandable stent |
US7090693B1 (en) | 2001-12-20 | 2006-08-15 | Boston Scientific Santa Rosa Corp. | Endovascular graft joint and method for manufacture |
US7641958B2 (en) | 2002-04-25 | 2010-01-05 | Gore Enterprise Holdings, Inc. | Membrane for use in sutured or sutureless surgical procedures |
WO2004082532A1 (en) * | 2003-03-17 | 2004-09-30 | Ev3 Sunnyvale, Inc. | Thin film composite lamination |
US7288084B2 (en) * | 2003-04-28 | 2007-10-30 | Boston Scientific Scimed, Inc. | Drug-loaded medical device |
US7811274B2 (en) * | 2003-05-07 | 2010-10-12 | Portaero, Inc. | Method for treating chronic obstructive pulmonary disease |
DE10329260A1 (de) | 2003-06-23 | 2005-01-13 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | Stent mit einem Beschichtungssystem |
US7735493B2 (en) | 2003-08-15 | 2010-06-15 | Atritech, Inc. | System and method for delivering a left atrial appendage containment device |
US20050060020A1 (en) * | 2003-09-17 | 2005-03-17 | Scimed Life Systems, Inc. | Covered stent with biologically active material |
US7056337B2 (en) * | 2003-10-21 | 2006-06-06 | Cook Incorporated | Natural tissue stent |
US8435285B2 (en) | 2003-11-25 | 2013-05-07 | Boston Scientific Scimed, Inc. | Composite stent with inner and outer stent elements and method of using the same |
US7530994B2 (en) * | 2003-12-30 | 2009-05-12 | Scimed Life Systems, Inc. | Non-porous graft with fastening elements |
JP2007517635A (ja) * | 2004-01-16 | 2007-07-05 | オステオバイオロジックス, インコーポレイテッド | 骨−腱−骨インプラント |
US7803178B2 (en) | 2004-01-30 | 2010-09-28 | Trivascular, Inc. | Inflatable porous implants and methods for drug delivery |
WO2005094725A1 (en) * | 2004-03-31 | 2005-10-13 | Merlin Md Pte Ltd | A method for treating aneurysms |
US8715340B2 (en) * | 2004-03-31 | 2014-05-06 | Merlin Md Pte Ltd. | Endovascular device with membrane |
US8500751B2 (en) | 2004-03-31 | 2013-08-06 | Merlin Md Pte Ltd | Medical device |
WO2005115259A2 (en) * | 2004-05-24 | 2005-12-08 | Biomedical Strategies | Wound closure system and methods |
US7794490B2 (en) * | 2004-06-22 | 2010-09-14 | Boston Scientific Scimed, Inc. | Implantable medical devices with antimicrobial and biodegradable matrices |
US20060009839A1 (en) * | 2004-07-12 | 2006-01-12 | Scimed Life Systems, Inc. | Composite vascular graft including bioactive agent coating and biodegradable sheath |
US20060020328A1 (en) * | 2004-07-23 | 2006-01-26 | Tan Sharon M L | Composite vascular graft having bioactive agent |
WO2006078320A2 (en) * | 2004-08-04 | 2006-07-27 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
WO2006026725A2 (en) | 2004-08-31 | 2006-03-09 | C.R. Bard, Inc. | Self-sealing ptfe graft with kink resistance |
US8703229B2 (en) * | 2004-09-22 | 2014-04-22 | Volcano Corporation | Method of making catheters with porous structure for carrying agents |
US7695753B2 (en) * | 2004-09-22 | 2010-04-13 | Volcano Corporation | Method of making catheters with porous structure for carrying additional agents |
GB0425854D0 (en) * | 2004-11-25 | 2004-12-29 | Astrazeneca Ab | Therapeutic treatment |
US8029563B2 (en) | 2004-11-29 | 2011-10-04 | Gore Enterprise Holdings, Inc. | Implantable devices with reduced needle puncture site leakage |
WO2006065665A1 (en) * | 2004-12-13 | 2006-06-22 | Robert Hunt Carpenter, Dvm, Pc | Multi-wall expandable device capable of drug delivery |
US20060233990A1 (en) | 2005-04-13 | 2006-10-19 | Trivascular, Inc. | PTFE layers and methods of manufacturing |
US20060233991A1 (en) | 2005-04-13 | 2006-10-19 | Trivascular, Inc. | PTFE layers and methods of manufacturing |
US20110076315A1 (en) * | 2005-06-08 | 2011-03-31 | C.R Bard, Inc. | Grafts and Stents Having Inorganic Bio-Compatible Calcium Salt |
JP2009501027A (ja) | 2005-06-17 | 2009-01-15 | シー・アール・バード・インコーポレイテツド | 締付後のよじれ耐性を有する血管移植片 |
US20100268321A1 (en) * | 2005-09-06 | 2010-10-21 | C R Bard, Inc. | Drug-releasing graft |
US7972359B2 (en) * | 2005-09-16 | 2011-07-05 | Atritech, Inc. | Intracardiac cage and method of delivering same |
EP2345376B1 (en) * | 2005-09-30 | 2012-07-04 | Cook Medical Technologies LLC | Coated vaso-occlusion device |
WO2007056761A2 (en) | 2005-11-09 | 2007-05-18 | C.R. Bard Inc. | Grafts and stent grafts having a radiopaque marker |
US20070112421A1 (en) * | 2005-11-14 | 2007-05-17 | O'brien Barry | Medical device with a grooved surface |
US20070135826A1 (en) * | 2005-12-01 | 2007-06-14 | Steve Zaver | Method and apparatus for delivering an implant without bias to a left atrial appendage |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
CA2642250A1 (en) * | 2006-02-13 | 2007-08-23 | Merlin Md Pte Ltd | Endovascular device with membrane |
US20070203564A1 (en) * | 2006-02-28 | 2007-08-30 | Boston Scientific Scimed, Inc. | Biodegradable implants having accelerated biodegradation properties in vivo |
US20070224235A1 (en) | 2006-03-24 | 2007-09-27 | Barron Tenney | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US20070254012A1 (en) * | 2006-04-28 | 2007-11-01 | Ludwig Florian N | Controlled degradation and drug release in stents |
JP5204384B2 (ja) * | 2006-05-19 | 2013-06-05 | 富士フイルム株式会社 | 結晶性ポリマー微孔性膜とその製造方法、および濾過用フィルター |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
US8771343B2 (en) | 2006-06-29 | 2014-07-08 | Boston Scientific Scimed, Inc. | Medical devices with selective titanium oxide coatings |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
CA2662808A1 (en) | 2006-09-14 | 2008-03-20 | Boston Scientific Limited | Medical devices with drug-eluting coating |
EP2959925B1 (en) | 2006-09-15 | 2018-08-29 | Boston Scientific Limited | Medical devices and methods of making the same |
JP2010503490A (ja) * | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | 調整可能な表面特徴を備えた内部人工器官 |
JP2010503494A (ja) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | 生分解性内部人工器官およびその製造方法 |
CA2663250A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making the same |
EP2210625B8 (en) | 2006-09-15 | 2012-02-29 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
CA2663762A1 (en) | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Endoprostheses |
US9198749B2 (en) | 2006-10-12 | 2015-12-01 | C. R. Bard, Inc. | Vascular grafts with multiple channels and methods for making |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
WO2008063539A2 (en) * | 2006-11-16 | 2008-05-29 | Boston Scientific Limited | Stent with differential timing of abluminal and luminal release of a therapeutic agent |
US10188534B2 (en) * | 2006-11-17 | 2019-01-29 | Covidien Lp | Stent having reduced passage of emboli and stent delivery system |
ES2506144T3 (es) | 2006-12-28 | 2014-10-13 | Boston Scientific Limited | Endoprótesis bioerosionables y procedimiento de fabricación de las mismas |
US20080172124A1 (en) * | 2007-01-11 | 2008-07-17 | Robert Lamar Bjork | Multiple drug-eluting coronary artery stent for percutaneous coronary artery intervention |
US9339593B2 (en) * | 2007-01-11 | 2016-05-17 | Robert L. Bjork, JR. | Drug-eluting coronary artery stent coated with anti-platelet-derived growth factor antibodies overlaying extracellular matrix proteins with an outer coating of anti-inflammatory (calcineurin inhibitor) and/or anti-proliferatives |
US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
AU2008254508B2 (en) * | 2007-05-17 | 2012-11-29 | Cook Medical Technologies Llc | Methods of making an endovascular prosthesis using a deformable matrix |
US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
US8721711B2 (en) * | 2007-06-20 | 2014-05-13 | Oregon Health & Science University | Graft having microporous membrane for uniform fluid infusion |
US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US9284409B2 (en) | 2007-07-19 | 2016-03-15 | Boston Scientific Scimed, Inc. | Endoprosthesis having a non-fouling surface |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
WO2009018340A2 (en) | 2007-07-31 | 2009-02-05 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
JP2010535541A (ja) | 2007-08-03 | 2010-11-25 | ボストン サイエンティフィック リミテッド | 広い表面積を有する医療器具用のコーティング |
US20090048657A1 (en) * | 2007-08-15 | 2009-02-19 | Boston Scientific Scimed, Inc. | Preferentially varying-density ePTFE structure |
JP5220369B2 (ja) * | 2007-09-04 | 2013-06-26 | 富士フイルム株式会社 | 結晶性ポリマー微孔性膜及びその製造方法、並びに濾過用フィルタ |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US20090076591A1 (en) * | 2007-09-19 | 2009-03-19 | Boston Scientific Scimed, Inc. | Stent Design Allowing Extended Release of Drug and/or Enhanced Adhesion of Polymer to OD Surface |
US8066755B2 (en) | 2007-09-26 | 2011-11-29 | Trivascular, Inc. | System and method of pivoted stent deployment |
US8663309B2 (en) | 2007-09-26 | 2014-03-04 | Trivascular, Inc. | Asymmetric stent apparatus and method |
US8226701B2 (en) | 2007-09-26 | 2012-07-24 | Trivascular, Inc. | Stent and delivery system for deployment thereof |
EP2194921B1 (en) | 2007-10-04 | 2018-08-29 | TriVascular, Inc. | Modular vascular graft for low profile percutaneous delivery |
US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8083789B2 (en) | 2007-11-16 | 2011-12-27 | Trivascular, Inc. | Securement assembly and method for expandable endovascular device |
US8328861B2 (en) | 2007-11-16 | 2012-12-11 | Trivascular, Inc. | Delivery system and method for bifurcated graft |
US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US7833266B2 (en) | 2007-11-28 | 2010-11-16 | Boston Scientific Scimed, Inc. | Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment |
EP2219725A4 (en) * | 2007-12-14 | 2011-05-18 | Univ Oregon Health & Science | CUFFS FOR ACTIVE INJECTION |
EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
EP2249893A2 (en) * | 2008-02-01 | 2010-11-17 | Boston Scientific Scimed, Inc. | Drug-coated medical devices for differential drug release |
JP2011512215A (ja) * | 2008-02-21 | 2011-04-21 | エグザカトゥ | 活性成分又は薬剤用、特に水溶性のもの用の保護/保持層を備える植込み型医用装置 |
EP2271380B1 (en) | 2008-04-22 | 2013-03-20 | Boston Scientific Scimed, Inc. | Medical devices having a coating of inorganic material |
WO2009132176A2 (en) | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
WO2009137384A2 (en) * | 2008-05-05 | 2009-11-12 | Boston Scientific Scimed, Inc. | Medical devices having a bioresorbable coating layer with a pre-determined pattern for fragmentation |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
EP2303350A2 (en) | 2008-06-18 | 2011-04-06 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7951193B2 (en) * | 2008-07-23 | 2011-05-31 | Boston Scientific Scimed, Inc. | Drug-eluting stent |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
JP4937977B2 (ja) * | 2008-09-02 | 2012-05-23 | 富士フイルム株式会社 | 結晶性ポリマー微孔性膜及びその製造方法、並びに濾過用フィルタ |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US20100086767A1 (en) * | 2008-10-06 | 2010-04-08 | General Electric Company | Processes For Producing Multilayer Polytetrafluoroethylene Articles And Articles Formed Therefrom |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
US20130268062A1 (en) | 2012-04-05 | 2013-10-10 | Zeus Industrial Products, Inc. | Composite prosthetic devices |
US8178030B2 (en) | 2009-01-16 | 2012-05-15 | Zeus Industrial Products, Inc. | Electrospinning of PTFE with high viscosity materials |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
JP5456892B2 (ja) | 2009-08-07 | 2014-04-02 | ゼウス インダストリアル プロダクツ インコーポレイテッド | 多層複合体 |
WO2011037953A2 (en) * | 2009-09-22 | 2011-03-31 | Surmodics Pharmaceuticals, Inc. | Implant devices having varying bioactive agent loading configurations |
US9320890B2 (en) * | 2009-11-09 | 2016-04-26 | W. L. Gore & Associates, Inc. | Drug eluting composite |
WO2011096402A1 (ja) | 2010-02-03 | 2011-08-11 | 独立行政法人物質・材料研究機構 | 生体適合性器具 |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US9839540B2 (en) | 2011-01-14 | 2017-12-12 | W. L. Gore & Associates, Inc. | Stent |
US10166128B2 (en) | 2011-01-14 | 2019-01-01 | W. L. Gore & Associates. Inc. | Lattice |
KR101241059B1 (ko) * | 2011-03-04 | 2013-03-11 | 연세대학교 산학협력단 | 마이크로 니들을 이용한 혈관외벽 장착 약물 전달장치 및 약물 전달방법 |
US9744033B2 (en) | 2011-04-01 | 2017-08-29 | W.L. Gore & Associates, Inc. | Elastomeric leaflet for prosthetic heart valves |
US9554806B2 (en) | 2011-09-16 | 2017-01-31 | W. L. Gore & Associates, Inc. | Occlusive devices |
JP2014530677A (ja) * | 2011-09-23 | 2014-11-20 | ゼウス インダストリアル プロダクツ インコーポレイテッド | 複合補綴シャントデバイス |
US9510935B2 (en) | 2012-01-16 | 2016-12-06 | W. L. Gore & Associates, Inc. | Articles including expanded polytetrafluoroethylene membranes with serpentine fibrils and having a discontinuous fluoropolymer layer thereon |
US8992595B2 (en) | 2012-04-04 | 2015-03-31 | Trivascular, Inc. | Durable stent graft with tapered struts and stable delivery methods and devices |
WO2013152327A1 (en) | 2012-04-06 | 2013-10-10 | Merlin Md Pte Ltd. | Devices and methods for treating an aneurysm |
US9498363B2 (en) | 2012-04-06 | 2016-11-22 | Trivascular, Inc. | Delivery catheter for endovascular device |
US9707504B2 (en) * | 2012-04-20 | 2017-07-18 | Daikin Industries, Ltd. | Composition having PTFE as main component, mixed powder, material for molding, filtering medium for filter, air filter unit, and a method for manufacturing a porous membrane |
US9283072B2 (en) | 2012-07-25 | 2016-03-15 | W. L. Gore & Associates, Inc. | Everting transcatheter valve and methods |
US10376360B2 (en) | 2012-07-27 | 2019-08-13 | W. L. Gore & Associates, Inc. | Multi-frame prosthetic valve apparatus and methods |
US9931193B2 (en) | 2012-11-13 | 2018-04-03 | W. L. Gore & Associates, Inc. | Elastic stent graft |
US9101469B2 (en) | 2012-12-19 | 2015-08-11 | W. L. Gore & Associates, Inc. | Prosthetic heart valve with leaflet shelving |
US10279084B2 (en) | 2012-12-19 | 2019-05-07 | W. L. Gore & Associates, Inc. | Medical balloon devices and methods |
US9144492B2 (en) | 2012-12-19 | 2015-09-29 | W. L. Gore & Associates, Inc. | Truncated leaflet for prosthetic heart valves, preformed valve |
US9968443B2 (en) | 2012-12-19 | 2018-05-15 | W. L. Gore & Associates, Inc. | Vertical coaptation zone in a planar portion of prosthetic heart valve leaflet |
US11167063B2 (en) | 2013-03-14 | 2021-11-09 | W. L. Gore & Associates, Inc. | Porous composites with high-aspect ratio crystals |
US11911258B2 (en) | 2013-06-26 | 2024-02-27 | W. L. Gore & Associates, Inc. | Space filling devices |
US20150073523A1 (en) * | 2013-09-10 | 2015-03-12 | Trivascular, Inc. | Endoleak isolation sleeves and methods of use |
US9814560B2 (en) | 2013-12-05 | 2017-11-14 | W. L. Gore & Associates, Inc. | Tapered implantable device and methods for making such devices |
US10842918B2 (en) | 2013-12-05 | 2020-11-24 | W.L. Gore & Associates, Inc. | Length extensible implantable device and methods for making such devices |
US20160302911A1 (en) * | 2013-12-27 | 2016-10-20 | Neograft Technologies, Inc. | Artificial graft devices and related systems and methods |
US9827094B2 (en) | 2014-09-15 | 2017-11-28 | W. L. Gore & Associates, Inc. | Prosthetic heart valve with retention elements |
ES2577883B2 (es) * | 2014-12-16 | 2016-11-21 | Universitat Politècnica De València | Biohíbrido para su uso en la regeneración de tractos neurales |
ES2908460T3 (es) | 2015-05-14 | 2022-04-29 | Gore & Ass | Dispositivos para la oclusión de un apéndice auricular |
AU2016270380B2 (en) | 2015-06-05 | 2019-04-04 | W. L. Gore & Associates, Inc. | A low bleed implantable prosthesis with a taper |
WO2017184153A1 (en) | 2016-04-21 | 2017-10-26 | W. L. Gore & Associates, Inc. | Diametrically adjustable endoprostheses and associated systems and methods |
CN110831520B (zh) | 2017-04-27 | 2022-11-15 | 波士顿科学国际有限公司 | 具有织物保持倒钩的闭塞医疗装置 |
US10959842B2 (en) | 2017-09-12 | 2021-03-30 | W. L. Gore & Associates, Inc. | Leaflet frame attachment for prosthetic valves |
CA3072781C (en) | 2017-09-27 | 2022-07-05 | W.L. Gore & Associates, Inc. | Prosthetic valves with mechanically coupled leaflets |
WO2019067219A1 (en) | 2017-09-27 | 2019-04-04 | W. L. Gore & Associates, Inc. | PROSTHETIC VALVE WITH EXTENSIBLE FRAME AND ASSOCIATED SYSTEMS AND METHODS |
EP3694445B1 (en) | 2017-10-13 | 2024-07-10 | Edwards Lifesciences Corporation | Telescoping prosthetic valve and delivery system |
US11173023B2 (en) | 2017-10-16 | 2021-11-16 | W. L. Gore & Associates, Inc. | Medical devices and anchors therefor |
JP7052032B2 (ja) | 2017-10-31 | 2022-04-11 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | 組織内方成長を促進する医療用弁及び弁膜 |
CN112714632B (zh) | 2018-08-21 | 2024-08-30 | 波士顿科学医学有限公司 | 用于心血管设备的带有倒钩的突出构件 |
US12115058B2 (en) * | 2019-02-22 | 2024-10-15 | Toray Industries, Inc. | Nerve regeneration-inducing tube |
US11497601B2 (en) | 2019-03-01 | 2022-11-15 | W. L. Gore & Associates, Inc. | Telescoping prosthetic valve with retention element |
JP2022535239A (ja) * | 2019-05-31 | 2022-08-05 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | 生体適合性メンブレン複合体 |
US11944314B2 (en) | 2019-07-17 | 2024-04-02 | Boston Scientific Scimed, Inc. | Left atrial appendage implant with continuous covering |
EP3986284A1 (en) | 2019-08-30 | 2022-04-27 | Boston Scientific Scimed, Inc. | Left atrial appendage implant with sealing disk |
KR20220081371A (ko) * | 2019-10-10 | 2022-06-15 | 더블유.엘. 고어 앤드 어소시에이트스, 인코포레이티드 | 세포 캡슐화 디바이스 |
US11083830B2 (en) * | 2019-10-14 | 2021-08-10 | Fresenius Medical Care Holdings, Inc. | Implantable fluid conduit |
CN110934662A (zh) * | 2019-12-31 | 2020-03-31 | 上海畅迪医疗科技有限公司 | 一种自带加强筋的人造血管 |
WO2021195085A1 (en) | 2020-03-24 | 2021-09-30 | Boston Scientific Scimed, Inc. | Medical system for treating a left atrial appendage |
CA3209727A1 (en) * | 2021-02-25 | 2022-09-01 | Edward H. Cully | Geometrically deformable implantable containment devices for retention of biological moieties |
CN118319553B (zh) * | 2024-06-13 | 2024-09-17 | 北京阿迈特医疗器械有限公司 | 一种人工血管及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0999056A (ja) * | 1995-06-07 | 1997-04-15 | Cook Inc | 医療装置 |
JPH10510196A (ja) * | 1995-03-10 | 1998-10-06 | インプラ・インコーポレーテッド | 体腔内用の封止型ステント及びその製造方法並びにその体腔内への導入方法 |
JPH11504548A (ja) * | 1996-01-22 | 1999-04-27 | ミードックス メディカルズ インコーポレイテッド | 改良ptfe人工血管およびその製造方法 |
WO2000032255A1 (en) * | 1998-12-03 | 2000-06-08 | Boston Scientific Limited | Polymeric coatings with controlled delivery of active agents |
JP2002510985A (ja) * | 1996-12-03 | 2002-04-09 | アトリウム メディカル コーポレーション | 多層式プロテーゼ |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4478898A (en) | 1982-06-04 | 1984-10-23 | Junkosha Co., Ltd. | Laminated porous polytetrafluoroethylene tube and its process of manufacture |
US5197977A (en) * | 1984-01-30 | 1993-03-30 | Meadox Medicals, Inc. | Drug delivery collagen-impregnated synthetic vascular graft |
ZW7487A1 (en) | 1986-05-23 | 1987-12-16 | Hoffmann La Roche | Tetrahydronaphthaline and indane derivatives |
US4816339A (en) | 1987-04-28 | 1989-03-28 | Baxter International Inc. | Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation |
US4955899A (en) * | 1989-05-26 | 1990-09-11 | Impra, Inc. | Longitudinally compliant vascular graft |
DE69110787T2 (de) | 1990-02-28 | 1996-04-04 | Medtronic, Inc., Minneapolis, Minn. | Intraluminale prothese mit wirkstoffeluierung. |
US5290271A (en) | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
US5370681A (en) * | 1991-09-16 | 1994-12-06 | Atrium Medical Corporation | Polyumenal implantable organ |
US5411550A (en) | 1991-09-16 | 1995-05-02 | Atrium Medical Corporation | Implantable prosthetic device for the delivery of a bioactive material |
US5229045A (en) * | 1991-09-18 | 1993-07-20 | Kontron Instruments Inc. | Process for making porous membranes |
US5316023A (en) * | 1992-01-08 | 1994-05-31 | Expandable Grafts Partnership | Method for bilateral intra-aortic bypass |
EP0630432B1 (en) | 1992-03-13 | 1999-07-14 | Atrium Medical Corporation | Controlled porosity expanded fluoropolymer (e.g. polytetrafluoroethylene) products and fabrication |
US5591224A (en) | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Bioelastomeric stent |
US5628782A (en) * | 1992-12-11 | 1997-05-13 | W. L. Gore & Associates, Inc. | Method of making a prosthetic vascular graft |
US5429634A (en) * | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
US5453235A (en) | 1993-01-29 | 1995-09-26 | Impra, Inc. | Method of forming dual porosity FTFE tubes by extrusion of concentric preforms |
US5399352A (en) * | 1993-04-14 | 1995-03-21 | Emory University | Device for local drug delivery and methods for using the same |
US5735892A (en) | 1993-08-18 | 1998-04-07 | W. L. Gore & Associates, Inc. | Intraluminal stent graft |
EP1217101B8 (en) * | 1994-04-29 | 2006-02-01 | Boston Scientific Scimed, Inc. | Stent with collagen |
US5665114A (en) | 1994-08-12 | 1997-09-09 | Meadox Medicals, Inc. | Tubular expanded polytetrafluoroethylene implantable prostheses |
AU719980B2 (en) * | 1995-02-22 | 2000-05-18 | Menlo Care, Inc. | Covered expanding mesh stent |
US6124523A (en) | 1995-03-10 | 2000-09-26 | Impra, Inc. | Encapsulated stent |
US5674242A (en) * | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
CA2178541C (en) * | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US5788626A (en) | 1995-11-21 | 1998-08-04 | Schneider (Usa) Inc | Method of making a stent-graft covered with expanded polytetrafluoroethylene |
US6120535A (en) * | 1996-07-29 | 2000-09-19 | Radiance Medical Systems, Inc. | Microporous tubular prosthesis |
ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
US5824050A (en) | 1996-12-03 | 1998-10-20 | Atrium Medical Corporation | Prosthesis with in-wall modulation |
US5897587A (en) | 1996-12-03 | 1999-04-27 | Atrium Medical Corporation | Multi-stage prosthesis |
AU3008599A (en) | 1998-03-18 | 1999-10-11 | Meadox Medicals, Inc. | Improved ptfe vascular prosthesis and method of manufacture |
US7597775B2 (en) | 2001-10-30 | 2009-10-06 | Boston Scientific Scimed, Inc. | Green fluoropolymer tube and endovascular prosthesis formed using same |
US6814561B2 (en) | 2001-10-30 | 2004-11-09 | Scimed Life Systems, Inc. | Apparatus and method for extrusion of thin-walled tubes |
-
2001
- 2001-09-25 US US09/962,062 patent/US6827737B2/en not_active Expired - Fee Related
-
2002
- 2002-07-16 CA CA2465704A patent/CA2465704C/en not_active Expired - Fee Related
- 2002-07-16 JP JP2003530345A patent/JP4651280B2/ja not_active Expired - Fee Related
- 2002-07-16 EP EP02756499A patent/EP1429816A1/en not_active Withdrawn
- 2002-07-16 EP EP07023795A patent/EP1925270B1/en not_active Expired - Lifetime
- 2002-07-16 WO PCT/US2002/022596 patent/WO2003026713A1/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10510196A (ja) * | 1995-03-10 | 1998-10-06 | インプラ・インコーポレーテッド | 体腔内用の封止型ステント及びその製造方法並びにその体腔内への導入方法 |
JPH0999056A (ja) * | 1995-06-07 | 1997-04-15 | Cook Inc | 医療装置 |
JPH11504548A (ja) * | 1996-01-22 | 1999-04-27 | ミードックス メディカルズ インコーポレイテッド | 改良ptfe人工血管およびその製造方法 |
JP2002510985A (ja) * | 1996-12-03 | 2002-04-09 | アトリウム メディカル コーポレーション | 多層式プロテーゼ |
WO2000032255A1 (en) * | 1998-12-03 | 2000-06-08 | Boston Scientific Limited | Polymeric coatings with controlled delivery of active agents |
Also Published As
Publication number | Publication date |
---|---|
EP1925270A2 (en) | 2008-05-28 |
EP1429816A1 (en) | 2004-06-23 |
US20030060871A1 (en) | 2003-03-27 |
JP2005503240A (ja) | 2005-02-03 |
CA2465704A1 (en) | 2003-04-03 |
US6827737B2 (en) | 2004-12-07 |
EP1925270B1 (en) | 2012-05-02 |
WO2003026713A1 (en) | 2003-04-03 |
EP1925270A3 (en) | 2008-06-04 |
CA2465704C (en) | 2010-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4651280B2 (ja) | 血管内人工器具用eptfe被覆材 | |
EP0604546B1 (en) | Extruded, controlled porosity implantable multi lumen device and method for making the same | |
JP4981665B2 (ja) | 抗菌剤と、生物分解性マトリックスと、外側の布層とを有する複合血管移植片 | |
US9855131B2 (en) | Vascular grafts with multiple channels and methods for making | |
EP1353606B1 (en) | Improved vascular prosthesis and method for production thereof | |
US5370681A (en) | Polyumenal implantable organ | |
US20050060020A1 (en) | Covered stent with biologically active material | |
EP1527754B1 (en) | Porous medicated stent | |
JP2007505687A5 (ja) | ||
US20010013166A1 (en) | Method of manufacturing a medicated porous metal prosthesis | |
JP2010518945A (ja) | 長期埋込み用の医用物品 | |
AU2002322505A1 (en) | ePTFE covering for endovascular prostheses | |
MXPA98002937A (es) | Metodo para fabricar una protesis de metal porosomedicada | |
MXPA98002936A (en) | Porosa medicated endoprotesis and method of |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050331 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080520 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080820 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090212 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090212 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090501 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091005 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20091021 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20091021 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20091029 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101027 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101122 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101214 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131224 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |